| Bid | 10.01 |
| Market Cap | 1.11B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.63 |
| PE Ratio (ttm) | -3.97 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.5 |
| Volume | 1,698,647 |
| Avg. Volume (20D) | 1,200,118 |
| Open | 10.88 |
| Previous Close | 10.73 |
| Day's Range | 10.32 - 10.93 |
| 52-Week Range | 10.28 - 31.47 |
| Beta | undefined |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...
Analyst Forecast
According to 10 analyst ratings, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $51, which is an increase of 388.27% from the latest price.
Next Earnings Release
Analysts project revenue of $31.30K, reflecting a n/a YoY growth and earnings per share of -0.72, making a 12.50% increase YoY.
3 weeks ago · investopedia.com
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeli...
1 month ago · businesswire.com
Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockCRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
2 months ago · https://thefly.com
Rocket Pharmaceuticals price target raised to $51 from $50 at ScotiabankScotiabank raised the firm's price target on Rocket Pharmaceuticals to $51 from $50 and keeps an Outperform rating on the shares. The company provided "a slew of positive updates," which included an a...
2 months ago · businesswire.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceCRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...